Both therapies are effective but demonstrate different patterns. TMS typically has a
40-60% response rate among patients with treatment-resistant depression, with about one-third achieving complete remission. These results develop gradually throughout therapy, usually becoming noticeable after 2-3 weeks of daily sessions. The effects of TMS tend to be long-lasting, with many patients maintaining improvements for six months to a year after treatment, though some may require additional sessions.
Ketamine has impressive initial response rates of up to 80%, with its most striking feature being the rapid onset of action. Many patients report significant improvement within hours to days after their first treatment, making it particularly valuable for crisis intervention. However, the duration of ketamine’s benefits can be shorter, typically lasting a few weeks to months. Therefore, regular maintenance treatments are required to sustain the therapeutic effects.
Regarding relapse rates, studies indicate that about 35-40% of TMS patients may experience some return of symptoms within the first year. However, they are often less severe than the original depression and can be effectively managed with maintenance sessions. Ketamine’s relapse rates tend to be higher, with one randomized controlled trial suggesting 77.8% of patients may experience the return of symptoms within a few weeks to months without regular follow-up treatments.
While ketamine offers rapid initial relief, TMS provides a more sustainable long-term solution with lower relapse rates and longer-lasting benefits. The gradual improvement seen with TMS often correlates with more stable neurological changes, potentially leading to more durable treatment outcomes requiring less frequent maintenance than ketamine’s ongoing schedule.